|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
EP3434774A1
(en)
|
2013-01-17 |
2019-01-30 |
ModernaTX, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
HRP20220070T1
(hr)
|
2014-04-23 |
2022-04-01 |
Modernatx, Inc. |
Cjepiva nukleinske kiseline
|
|
EP4023755B1
(en)
|
2014-12-12 |
2023-04-26 |
CureVac SE |
Artificial nucleic acid molecules for improved protein expression
|
|
WO2016100812A1
(en)
*
|
2014-12-19 |
2016-06-23 |
Moderna Therapeutics, Inc. |
Terminal modifications of polynucleotides
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
EP3328394A4
(en)
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
CONCATEMEE peptide epitope RNAs
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
SG11201803360UA
(en)
|
2015-10-22 |
2018-05-30 |
Modernatx Inc |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
EP3364949A4
(en)
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
MA45209A
(fr)
|
2015-10-22 |
2019-04-17 |
Modernatx Inc |
Vaccins contre les maladies sexuellement transmissibles
|
|
DE20164728T1
(de)
|
2015-10-22 |
2021-09-30 |
Modernatx, Inc. |
Impfstoffe gegen atemwegsvirus
|
|
DK3386484T3
(da)
|
2015-12-10 |
2022-07-04 |
Modernatx Inc |
Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
|
|
CN109475568B
(zh)
|
2016-05-06 |
2026-07-17 |
Ionis制药公司 |
Glp-1受体配体部分缀合的寡核苷酸及其用途
|
|
US11801227B2
(en)
|
2016-05-18 |
2023-10-31 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
MX2019000205A
(es)
|
2016-07-07 |
2019-09-23 |
Rubius Therapeutics Inc |
Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
|
|
SG11201901941YA
(en)
|
2016-09-14 |
2019-04-29 |
Modernatx Inc |
High purity rna compositions and methods for preparation thereof
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
|
BR112019010486A2
(pt)
*
|
2016-11-28 |
2019-09-10 |
Napajen Pharma Inc |
sirna quimicamente modificado
|
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
|
EP3555289A1
(en)
|
2016-12-13 |
2019-10-23 |
ModernaTX, Inc. |
Rna affinity purification
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170347A1
(en)
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
|
KR102050870B1
(ko)
*
|
2017-04-06 |
2019-12-02 |
포항공과대학교 산학협력단 |
무항생제 플라스미드 유지 시스템에서 플라스미드 카피 수의 정량적 조절 방법
|
|
WO2018206125A1
(en)
|
2017-05-09 |
2018-11-15 |
Fundacion Para La Investigacion Medica Aplicada |
Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
WO2019036682A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
RNA VARIANTS POLYMERASE
|
|
EP3668977A4
(en)
|
2017-08-18 |
2021-04-21 |
Modernatx, Inc. |
HPLC ANALYTICAL PROCESSES
|
|
WO2019036685A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR HPLC ANALYSIS
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
GB201714430D0
(en)
*
|
2017-09-07 |
2017-10-25 |
Micol Romain |
Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
|
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
RNA VACZINE AGAINST ZIKA VIRUS
|
|
AU2018364621A1
(en)
*
|
2017-11-08 |
2020-06-18 |
Astrazeneca Ab |
GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
|
|
CN111712468A
(zh)
|
2017-12-22 |
2020-09-25 |
北卡罗莱纳州立大学 |
聚合物荧光团、包含其的组合物及制备和使用其的方法
|
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
|
US20200376142A1
(en)
*
|
2018-02-19 |
2020-12-03 |
Combined Therapeutics, Inc. |
Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
|
|
US12151029B2
(en)
|
2018-09-19 |
2024-11-26 |
Modernatx, Inc. |
PEG lipids and uses thereof
|
|
CN112996854B
(zh)
|
2018-09-19 |
2024-08-30 |
摩登纳特斯有限公司 |
高纯度peg脂质和其用途
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN113939282A
(zh)
|
2019-01-31 |
2022-01-14 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
MX2021010075A
(es)
|
2019-02-20 |
2021-12-10 |
Modernatx Inc |
Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
|
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
|
MX2021011031A
(es)
|
2019-03-11 |
2021-12-10 |
Modernatx Inc |
Proceso de transcripción in vitro en lotes alimentados.
|
|
MA55321A
(fr)
|
2019-03-15 |
2022-01-19 |
Modernatx Inc |
Vaccins à base d'arn contre le vih
|
|
US20220170062A1
(en)
*
|
2019-04-05 |
2022-06-02 |
Kyoto University |
Rna capping method, production method for modified rna, and modified rna
|
|
WO2021001377A1
(en)
|
2019-07-02 |
2021-01-07 |
Fundacion Para La Investigacion Medica Aplicada |
cPLA2e INDUCING AGENTS AND USES THEREOF
|
|
CN118490818A
(zh)
|
2020-04-22 |
2024-08-16 |
生物技术欧洲股份公司 |
冠状病毒疫苗
|
|
JP2023536844A
(ja)
|
2020-07-31 |
2023-08-30 |
コンバインド セラピューティクス インコーポレイテッド |
ワクチン接種を改善するための組成物および方法
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP4217377A4
(en)
*
|
2020-09-23 |
2024-11-27 |
Myeloid Therapeutics, Inc. |
Improved methods and compositions for expression of nucleic acids in cells
|
|
WO2022150717A1
(en)
|
2021-01-11 |
2022-07-14 |
Modernatx, Inc. |
Seasonal rna influenza virus vaccines
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
EP4326227A1
(en)
|
2021-04-23 |
2024-02-28 |
ModernaTX, Inc. |
Stabilized formulations
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
TW202317766A
(zh)
*
|
2021-06-24 |
2023-05-01 |
南韓商韓美藥品股份有限公司 |
非自然發生的5’-非轉譯區及3’-非轉譯區及其用途
|
|
KR20240026181A
(ko)
|
2021-06-30 |
2024-02-27 |
쿄와 기린 가부시키가이샤 |
폴리뉴클레오티드 및 의약 조성물
|
|
JP7689238B2
(ja)
*
|
2021-07-27 |
2025-06-05 |
エスケー バイオサイエンス カンパニー リミテッド |
タンパク質発現のためのｍＲＮＡ、及びそのためのテンプレート
|
|
KR20240090727A
(ko)
|
2021-10-22 |
2024-06-21 |
세일 바이오메디슨스, 인크. |
Mrna 백신 조성물
|
|
US20250002941A1
(en)
|
2021-11-23 |
2025-01-02 |
Sail Biomedicines, Inc. |
A bacteria-derived lipid composition and use thereof
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
EP4452239A1
(en)
|
2021-12-20 |
2024-10-30 |
Sail Biomedicines, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
US12529047B1
(en)
|
2021-12-21 |
2026-01-20 |
Modernatx, Inc. |
mRNA quantification methods
|
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
|
KR20250019772A
(ko)
|
2022-05-25 |
2025-02-11 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
종양 억제인자 및 발암유전자를 조절하기 위한 조성물 및 방법
|
|
CN119563038A
(zh)
|
2022-05-25 |
2025-03-04 |
旗舰创业创新七公司 |
用于调节免疫应答的组合物和方法
|
|
AU2023275550A1
(en)
|
2022-05-25 |
2024-11-21 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating cytokines
|
|
AU2023277636A1
(en)
|
2022-05-25 |
2024-11-21 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating genetic drivers
|
|
EP4650780A3
(en)
|
2022-05-25 |
2026-01-21 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods for modulating circulating factors
|
|
US11878055B1
(en)
|
2022-06-26 |
2024-01-23 |
BioNTech SE |
Coronavirus vaccine
|
|
US20260049286A1
(en)
*
|
2022-08-08 |
2026-02-19 |
The Curators Of The University Of Missouri |
Fasl-modified plg scaffolds enhances differentiation of stem cell derived beta cells
|
|
WO2024044147A1
(en)
|
2022-08-23 |
2024-02-29 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
|
EP4615424A1
(en)
|
2022-11-10 |
2025-09-17 |
Sail Biomedicines, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
JP2026503676A
(ja)
|
2023-01-27 |
2026-01-29 |
セイル バイオメディシンズ インコーポレイテッド |
修飾脂質組成物およびその使用
|
|
EP4698150A1
(en)
|
2023-04-19 |
2026-02-25 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
JP2026518711A
(ja)
|
2023-05-16 |
2026-06-09 |
フラッグシップ ラブズ １１４， インコーポレイテッド |
標的遺伝子のメチル化を調節するための方法及び組成物
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
TW202517780A
(zh)
*
|
2023-09-27 |
2025-05-01 |
南韓商韓美藥品股份有限公司 |
包括非天然５＇非轉譯區的傳訊核糖核酸、對其進行編碼的脫氧核糖核酸以及包含其的組成物
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|
|
WO2026036000A1
(en)
|
2024-08-08 |
2026-02-12 |
Invaio Sciences, Inc. |
Nature-derived lipid particles for use in agriculture
|